Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

Rhea-AI Summary

Omeros Corporation (Nasdaq: OMER) will present two studies on its investigational complement inhibitors at the 64th American Society of Hematology Annual Meeting from December 10-13, 2022, in New Orleans. The first presentation focuses on the safety and pharmacokinetics of the MASP-3 inhibitor OMS906 (Abstract #2570), scheduled for December 11. The second presentation evaluates the MASP-2 inhibitor Narsoplimab for pediatric patients with HSCT-TMA (Abstract #3808) on December 12. Poster details will be available on Omeros' website post-meeting.

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) today announced that two presentations pertaining to Omeros’ investigational complement inhibitors will be featured at the upcoming 64th American Society of Hematology (ASH) Annual Meeting, which will be held from December 10-13, 2022 in New Orleans. The following abstracts were published today and are now available on the ASH website at www.hematology.org:

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Alternative Pathway MASP-3 Inhibitor OMS906 in a Phase 1 Study of Healthy Subjects (Abstract #2570)
Session Name: 508. Bone Marrow Failure: Acquired: Poster II
Date: Sunday, December 11, 2022
Presentation Time: 6:00 p.m. - 8:00 p.m. ET
Location: Ernest N. Morial Convention Center, Hall D

Trial in Progress: An Open-Label, Multi-Center Phase 2 Study Evaluating Efficacy and Safety of the MASP-2 Inhibitor Narsoplimab in Pediatric Patients with High-Risk Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA) (Abstract #3808)
Session Name: 331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological: Poster III
Date: Monday, December 12, 2022
Presentation Time: 6:00 p.m. - 8:00 p.m. ET
Location: Ernest N. Morial Convention Center, Hall D

Following presentation at the meeting, the posters will be available on Omeros’ website at www.omeros.com

About Omeros Corporation

Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application (BLA) pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, COVID-19, and atypical hemolytic uremic syndrome. Omeros’ long-acting MASP-2 inhibitor OMS1029 is currently in a Phase 1 clinical trial. OMS906, Omeros’ inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria (PNH), complement 3 (C3) glomerulopathy and one or more related indications. For more information about Omeros and its programs, visit www.omeros.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005648/en/

Jennifer Cook Williams

Cook Williams Communications, Inc.

Investor and Media Relations

IR@omeros.com

Source: Omeros Corporation

FAQ

What studies is Omeros presenting at the ASH Annual Meeting in December 2022?

Omeros will present studies on OMS906 and Narsoplimab, focusing on complement inhibitors.

When is Omeros presenting OMS906 at the ASH meeting?

The presentation on OMS906 is scheduled for December 11, 2022.

What is the significance of the study on Narsoplimab presented by Omeros?

The Narsoplimab study evaluates its efficacy and safety in pediatric patients with HSCT-TMA.

Where can I find the presentations from Omeros after the ASH meeting?

Post-meeting presentations will be available on Omeros' website.

What are the dates for the ASH Annual Meeting 2022?

The ASH Annual Meeting will take place from December 10-13, 2022.